key: cord-0819254-twdv94x2
authors: Zhang, Bin; Liu, Shuyi; Zhang, Lu; Dong, Yuhao; Zhang, Shuixing
title: Admission fasting blood glucose predicts 30‐day poor outcome in patients hospitalized for COVID‐19 pneumonia
date: 2020-07-06
journal: Diabetes Obes Metab
DOI: 10.1111/dom.14132
sha: 03b23d39b3bc9705efb8fb5cd807bff0bc8772bd
doc_id: 819254
cord_uid: twdv94x2

nan

Patients with laboratory-confirmed COVID-19 who admitted to six designated hospitals for COVID-19 treatment from January 1 to March 31, 2020 were retrospectively enrolled.

We collected clinical and laboratory data at hospital admission. A semiquantitative computed tomography (CT) scoring system was designed to assess the involvement degree or area of pneumonia for each lung lobe (total 5 lung lobes): 0 for 0% involvement; 1 for 1-25% involvement; 2 for 26-50% involvement; 3 for 51-75% involvement; 4 for 76-100% involvement (6) . A CT score (range, 0-20) was assigned by summarizing the total scores of five lobes. CT images were reviewed independently by two radiologists with >10 years of experience. Poor 30-day outcome was defined as composite adverse endpoints, including ARDS, ICU admission, septic shock, MOD, or death within 30 days after admission. ARDS was defined according to the Berlin definition (7) . Criteria for MOD included multilobar infiltrates and other organ damage, such as damage to cardiovascular system, acute liver function damage, and acute kidney injury (8) . Baseline features were compared between patients with poor and good 30-day outcome (Appendix 1). The optimal cutoff FBG for discriminating COVID-19 patients with poor and good outcome was determined by receiver operating characteristic analysis (Appendix 2) and by maximizing the Youden index. To identify predictors for poor 30-day outcome, baseline variables with p value <0.10 in univariable analysis were entered into multivariate logistic regression. After adjusting for pre-existing diabetes, the OR of FBG increased to 1.217 (95% CI: 1.054-1.405, P = 0.008).

We found that admission FBG was an independent predictor for 30-day outcome of COVID-19 patients. Hyperglycemia is mainly caused by diabetes and stress or acute hyperglycemia (9) . The pooled prevalence for diabetes in patients with COVID-19 was 11.5% according to a recent meta-analysis (10) . Diabetes has been identified as a crucial risk factor for mortality and progression in hospitalized patients with COVID-19 (11) . COVID-19 patients with diabetes may also produce severe complications, such as ketosis or ketoacidosis, and induced diabetic ketoacidosis (12) . Patients with newly diagnosed diabetes had worse outcomes than those with known diabetes (13) . Acute hyperglycemia has been often observed in patients without diabetes, which may be induced by a decrease of insulin secretion and the appearance/worsening of insulin resistance (14) . Acute hyperglycemia may cause organ damage by inducing endothelial dysfunction and thrombosis through glycation process and oxidative stress generation (14) . Continuous glucose monitoring is necessary for patients with diabetes and acute hyperglycemia. Glucose control helps prevent and control infections and their complications. Therefore, well-controlled blood glucose may lead to an improved outcomes for patients with COVID-19 (15, 16) . This article is protected by copyright. All rights reserved.

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score

Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19

An interpretable mortality prediction model for COVID-19 patients

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Acute respiratory distress syndrome: the Berlin Definition

CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients

The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan

Prevalence of comorbidities and their association with mortality in patients with COVID-19: A Systematic Review and Meta-analysis

Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection

COVID-19 infection may cause ketosis and ketoacidosis

Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19

Why is hyperglycaemia worsening COVID-19 and its prognosis?

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care